Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple myeloma.

N Raje1, K C Anderson

  • 1Adult Oncology, Dana-Farber Cancer Institute Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A high-throughput platform for biophysical antibody developability assessment to enable AI/ML model training.

mAbs·2025
Same author

Retraction Note: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide.

Leukemia·2024
Same author

Neurologic Outcomes After Radiation Therapy for Severe Spinal Cord Compression in Multiple Myeloma: A Study of 162 Patients.

The Journal of bone and joint surgery. American volume·2023
Same author

Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials.

Seminars in hematology·2023
Same author

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Leukemia·2019
Same author

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

Leukemia·2018
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Multiple myeloma (MM) is a fatal plasma cell cancer with limited survival. Novel therapies, including thalidomide and immune-based strategies, are needed to improve patient outcomes as current treatments offer only temporary remission.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Multiple myeloma (MM) is an incurable plasma cell malignancy with a median survival of 3-4 years despite decades of research.
  • Current treatments, including chemotherapy and high-dose chemotherapy with autologous stem cell transplantation, offer limited survival benefits and do not prevent relapse.

Purpose of the Study:

  • To review current therapeutic strategies for multiple myeloma (MM).
  • To highlight the limitations of existing treatments and the urgent need for novel therapeutic approaches.
  • To discuss emerging immune-based strategies for MM treatment.

Main Methods:

  • Review of existing literature on multiple myeloma treatments.
  • Analysis of survival data and treatment response rates.

Related Experiment Videos

  • Exploration of novel therapeutic avenues, including thalidomide and immunotherapy.

    • Main Results:

    • High-dose chemotherapy with autologous stem cell transplantation shows benefit over conventional therapy but does not prevent relapse.
    • Allogeneic transplantation has high remission rates but significant mortality.
    • Bisphosphonates reduce bone disease morbidity.
    • Thalidomide shows encouraging responses in MM patients.

    Conclusions:

    • Despite advances, multiple myeloma remains a fatal disease with inevitable relapse.
    • Novel therapeutic strategies are essential for improving patient outcomes.
    • Immune-based strategies, such as immunotherapy and vaccination, hold promise for enhancing anti-MM immunity.